Stryker Corp revenue by segment SYK

Annual Quarterly

Stryker Corp splits its revenue 2 ways in its filings. By operating segments, the largest line in fiscal 2025, which ended Dec 31, 2025 was Med Surg And Neurotechnology at $15.6 billion, 62% of the total. By sales mix, the largest line in fiscal 2025, which ended Dec 31, 2025 was Medical at $4.2 billion, 17% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	26,300	25,116	22,595	20,498	18,449	17,108	14,351	14,884	13,601	12,444	11,325
Operating segments
Med Surg And Neurotechnology	—	15,647 +15.7% share 62.3%	13,518 +11.1% share 59.8%	12,163 +14.6% share 59.3%	10,611 +11.2% share 57.5%	9,538 +14.3% share 55.8%	8,345 -1.5% share 58.1%	8,475 share 56.9%	—	—	—
Orthopaedics And Spine	—	9,469 +4.3% share 37.7%	9,077 +8.9% share 40.2%	8,335 +6.3% share 40.7%	7,838 +3.5% share 42.5%	7,570 +26.0% share 44.2%	6,006 -6.3% share 41.9%	6,409 share 43.1%	—	—	—
Sales mix
Medical	—	4,204 +9.1% share 16.7%	3,852 +11.4% share 17.0%	3,459 +14.1% share 16.9%	3,031 +16.3% share 16.4%	2,607 +3.3% share 15.2%	2,524 +11.5% share 17.6%	2,264 +6.9% share 15.2%	2,118 +7.6% share 15.6%	1,969 share 15.8%	—
Traumaand Extremities	—	3,948 +12.6% share 15.7%	3,507 +11.4% share 15.5%	3,147 +12.1% share 15.4%	2,807 +5.4% share 15.2%	2,664 +54.7% share 15.6%	1,722 +5.1% share 12.0%	1,639 +3.7% share 11.0%	1,580 +6.9% share 11.6%	1,478 share 11.9%	—
Endoscopy	—	3,807 +12.3% share 15.2%	3,389 +10.5% share 15.0%	3,068 +12.6% share 15.0%	2,725 +12.7% share 14.8%	2,418 +37.2% share 14.1%	1,763 share 12.3%	—	1,846 +11.7% share 13.6%	1,652 share 13.3%	—
Instruments	—	3,183 +12.3% share 12.7%	2,834 share 12.5%	—	—	2,111 +13.3% share 12.3%	1,863 -4.9% share 13.0%	1,959 +7.5% share 13.2%	1,822 +8.6% share 13.4%	1,678 share 13.5%	—
Knees	—	2,656 +8.5% share 10.6%	2,447 +7.7% share 10.8%	2,273 share 11.1%	—	1,848 +17.9% share 10.8%	1,567 -13.7% share 10.9%	1,815 +6.7% share 12.2%	1,701 +6.6% share 12.5%	1,595 share 12.8%	—
Neuro Cranial	—	2,485 +16.3% share 9.9%	2,136 +13.9% share 9.5%	1,876 +36.3% share 9.2%	1,376 +13.3% share 7.5%	1,214 +24.9% share 7.1%	972 -8.2% share 6.8%	1,059 share 7.1%	—	—	—
Neurovascular	—	1,968 +50.6% share 7.8%	1,307 +6.6% share 5.8%	1,226 +2.2% share 6.0%	1,200 +1.0% share 6.5%	1,188 +22.1% share 6.9%	973 +5.3% share 6.8%	924 share 6.2%	—	—	—
Hips	—	1,865 +9.4% share 7.4%	1,704 +10.4% share 7.5%	1,544 +9.3% share 7.5%	1,413 +5.3% share 7.7%	1,342 +11.3% share 7.8%	1,206 -12.8% share 8.4%	1,383 +3.5% share 9.3%	1,336 +2.5% share 9.8%	1,303 share 10.5%	—
Other Orthopaedics	—	815 +14.5% share 3.2%	712 +8.2% share 3.2%	658 +38.5% share 3.2%	475 -13.5% share 2.6%	549 +119.6% share 3.2%	250 -12.6% share 1.7%	286 share 1.9%	—	—	—
Spinal Implants	—	185 -73.8% share 0.7%	707 -0.8% share 3.1%	713 -37.8% share 3.5%	1,146 -1.8% share 6.2%	1,167 +11.5% share 6.8%	1,047 -9.5% share 7.3%	1,157 +39.7% share 7.8%	828 +10.3% share 6.1%	751 share 6.0%	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as: SYK (NYSE)
Fiscal year ends: December 31
Incorporated in: MI
Headquarters: Portage, MI
SEC filer status: Large accelerated filer
SEC CIK: 310764

Other Surgical & Medical Instruments & Apparatus companies

All 151 Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.